Organization (Industry)
Arbor Pharmaceuticals (United States)
ClinicalTrials.gov lists Arbor Pharmaceuticals (United States) as lead sponsor of 15 trials. It has 9 active development programs and 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Arbor Pharmaceuticals (United States): 15 lead-sponsored trials and 1 legal-entity registration.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 3 |
| Otitis Media | 3 |
| Pain | 3 |
| Earache | 2 |
| Alcoholism | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 3 |
| 2014 | 2 |
| 2013 | 5 |
| 2012 | 2 |
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Azilsartan Medoxomil Medium-dose (20 mg) | Essential Hypertension | Phase 3 | 1 |
| Azilsartan Medoxomil Medium-dose (20 mg) | Hypertension | Phase 3 | 1 |
| Azilsartan Medoxomil High-dose (40 mg) | Essential Hypertension | Phase 3 | 1 |
| Azilsartan Medoxomil High-dose (40 mg) | Hypertension | Phase 3 | 1 |
| Azilsartan Medoxomil Low-dose | Essential Hypertension | Phase 3 | 1 |
Showing 5 of 9 active programs.
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg | 1 |
| Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg | 1 |
| Oxycodone 20 mg | 1 |
| Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg | 1 |
| GE-IR 200 mg | 1 |
Showing 5 of 11 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 2 of 3 on time (n=3) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Advances in therapy | 1 |
| CNS oncology | 1 |
| Current therapeutic research, clinical and experimental | 1 |
| Journal of child and adolescent psychopharmacology | 1 |
| The Journal of clinical psychiatry | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 21 | 8 | 2025-10-14 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 4 |
FDA recalls (3)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Nymalize (nimodipine) oral solution, 60 mg/20 mL, 12 Unit-Dose Cups and 12 Oral Syringes, 2 inner cartons per outer shipping carton, Rx Only, Distributed by arbor Atlanta, GA, NDC 24338-200-12 | Class III | 2020-09-16 |
| Testosterone Cypionate Injection, USP, 2000 mg/10 mL, 1 mL Vial, Single-Dose, Rx only, Mfd. for: Wilshire Pharmaceuticals, Inc. Atlanta, GA 30328. NDC 52536-625-01 | Class III | 2019-09-27 |
| Cetylev (acetylcysteine) effervescent tablets for oral solution, 500 mg, Rx Only, 20 tablets per carton (ten 2 count blister packs), Distributed by Arbor Pharmaceuticals, LLC Atlanta, GA 30328, NDC 24338-700-10. | Class I | 2016-07-21 |
Latest dated events (45)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-06 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-03-26 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-12-26 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-08-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 45 events.
Biomarker capability evidence (32)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FDPS | Trial sponsor | Named in trial inclusion criteria |
| FDPS | Trial sponsor | Named in trial inclusion criteria |
| FDPS | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FDPS | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FES | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 32 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.